Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
National Cancer Institute of Canada |
---|---|
Information provided by: | National Cancer Institute (NCI) |
ClinicalTrials.gov Identifier: | NCT00516828 |
RATIONALE: Sorafenib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth or by blocking blood flow to the cancer. Drugs used in chemotherapy, such as cytarabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving sorafenib together with cytarabine may kill more cancer cells.
PURPOSE: This phase I/II trial is studying the side effects and best dose of giving sorafenib together with cytarabine and to see how well it works in treating older patients with acute myeloid leukemia or high-risk myelodysplastic syndrome.
Condition | Intervention | Phase |
---|---|---|
Leukemia Myelodysplastic Syndromes |
Drug: cytarabine Drug: sorafenib tosylate Procedure: biopsy Procedure: laboratory biomarker analysis Procedure: mutation analysis |
Phase I Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized |
Official Title: | A Phase I/II Study of Sorafenib (BAY 43-9006) in Combination With Low Dose ARA-C (CYTARABINE) in Elderly Patients With AML or High-Risk MDS |
Estimated Enrollment: | 47 |
Study Start Date: | July 2007 |
Estimated Primary Completion Date: | April 2010 (Final data collection date for primary outcome measure) |
OBJECTIVES:
OUTLINE: This is a multicenter study.
Bone marrow (or blood) samples are collected at baseline and at the end of each course of study treatment. Baseline samples are analyzed for mutational status of FLT-3 (i.e., internal tandem duplication [ITD] and point mutations).
After completion of study treatment, patients are followed at 4 weeks and then every 3 months thereafter.
PROJECTED ACCRUAL: A total of 47 will be accrued for this study.
Ages Eligible for Study: | 60 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
DISEASE CHARACTERISTICS:
Diagnosis of 1 of the following:
PATIENT CHARACTERISTICS:
No serious illness or medical condition that would not permit the patient to be managed according to the protocol, including any of the following:
PRIOR CONCURRENT THERAPY:
No concurrent therapeutic doses (≥ 2 mg/day) of anticoagulants (e.g., warfarin)
Canada, Nova Scotia | |
Nova Scotia Cancer Centre | Recruiting |
Halifax, Nova Scotia, Canada, B3H 1V7 | |
Contact: David A. MacDonald 902-473-3596 | |
Canada, Ontario | |
Margaret and Charles Juravinski Cancer Centre | Recruiting |
Hamilton, Ontario, Canada, L8V 5C2 | |
Contact: Brian Leber 905-521-2100 | |
Princess Margaret Hospital | Recruiting |
Toronto, Ontario, Canada, M5G 2M9 | |
Contact: Joseph Brandwein 416-946-2824 | |
Canada, Quebec | |
McGill Cancer Centre at McGill University | Recruiting |
Montreal, Quebec, Canada, H2W 1S6 | |
Contact: Sarit Assouline 514-340-8207 |
Study Chair: | Brian Leber, MD, FRCPC | McMaster Children's Hospital at Hamilton Health Sciences |
Study Chair: | David A. MacDonald, MD | Nova Scotia Cancer Centre |
Study ID Numbers: | CDR0000560975, CAN-NCIC-IND186 |
Study First Received: | August 14, 2007 |
Last Updated: | July 23, 2008 |
ClinicalTrials.gov Identifier: | NCT00516828 |
Health Authority: | Unspecified |
adult acute myeloid leukemia with 11q23 (MLL) abnormalities adult acute myeloid leukemia with inv(16)(p13;q22) adult acute myeloid leukemia with t(15;17)(q22;q12) adult acute myeloid leukemia with t(16;16)(p13;q22) adult acute myeloid leukemia with t(8;21)(q22;q22) |
untreated adult acute myeloid leukemia secondary acute myeloid leukemia de novo myelodysplastic syndromes secondary myelodysplastic syndromes |
Myelodysplastic syndromes Precancerous Conditions Hematologic Diseases Myelodysplastic Syndromes Myelodysplasia Acute myelogenous leukemia Leukemia, Myeloid Leukemia, Myeloid, Acute Leukemia |
Preleukemia Neoplasm Metastasis Acute myeloid leukemia, adult Congenital Abnormalities Bone Marrow Diseases Sorafenib Acute myelocytic leukemia Cytarabine |
Antimetabolites Anti-Infective Agents Neoplasms by Histologic Type Disease Antimetabolites, Antineoplastic Immunologic Factors Molecular Mechanisms of Pharmacological Action Antineoplastic Agents Physiological Effects of Drugs |
Enzyme Inhibitors Protein Kinase Inhibitors Immunosuppressive Agents Antiviral Agents Pharmacologic Actions Neoplasms Pathologic Processes Syndrome Therapeutic Uses |